TNFRSF17 and Miyoshi myopathy: Anti-BCMA immunotherapies, together with APRIL inhibition, can defeat MM-induced immunosuppressive microenvironment and intensify the ADCC (antibody-dependent cell-mediated cytotoxicity) against myeloma cells[31,35,43].